Bollard Group LLC Blueprint Medicines Corp Transaction History

Bollard Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$90.71 - $108.28 $907,099 - $1.08 Million	-10,000 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$72.9 - $101.41 $729,000 - $1.01 Million	10,000 New	10,000 $735,000
Q2 2019 Aug 13, 2019	SELL	$73.54 - $97.8 $3.48 Million - $4.63 Million	-47,300 Closed	0 $0
Q4 2018 Feb 05, 2019	BUY	$45.57 - $74.26 $82,026 - $133,668	1,800 Added 3.96%	47,300 $2.55 Million
Q3 2018 Nov 08, 2018	SELL	$58.91 - $78.32 $441,825 - $587,400	-7,500 Reduced 14.15%	45,500 $3.55 Million
Q2 2018 Aug 09, 2018	BUY	$60.96 - $101.18 $899,160 - $1.49 Million	14,750 Added 38.56%	53,000 $3.36 Million
Q1 2018 May 14, 2018	BUY	$73.28 - $102.95 $2.8 Million - $3.94 Million	38,250 New	38,250 $3.51 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Bollard Group LLC, based on Form 13F filings with the SEC.

Stay updated on Bollard Group LLC with notifications on news.